Numeral 12 — NOM-035-SSA2-2012, Para la prevención y control de enfermedades en la perimenopausia y postmenopausia de la mujer. Criterios para brindar atención médica

12 Bibliografía

12.1 American Dietetic Association. Disorders of lipid metabolism evidence-based nutrition practice

guidelines. Evidence Analysis Library. 2005.

12.2 Beral V, et al. For the Million Women Study Coll aborators. Breast cancer and hormone-replacement

therapy in the Million Women Study. Lancet 2003; 362:419-427.

12.3 Barrett-Connor E, Grady E, Sashegy A, Ande rson PW, Cox DA, Hoszowski K, et al. MORE

investigators (Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular events in

osteoporotic postmenopausal women: four-year results from the MORE randomized trial. JAMA 2002;

287:847-857.

12.4 Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Ti bolone: prevention of bone

mass in late postmenopausal women. J Clin Endocrinol Metab 1996; 81:2419-2422.

12.5 Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause

transition. Recent Prog Horm Res 2002; 57:257-275.

12.6 Canto-de-Cetina TE, Canto-Cetina P, Polanco-Reyes L. Survey of climacteric symptoms in semi-rural

areas of Yucatán. Rev. Invest. Clín. 1998; 50:133-135.

12.7 Chávez Galindo AM, Uribe Zúñiga P, Palma Cabrer a Y. (Coordinadoras) La Salud Reproductiva en

México. Análisis de la Encuesta Nacional de Salud Re productiva 2003. Secretaría de Salud, México, D.F.,

México, 2007, pp. 220-226.

12.8 Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the

menopausal transition. The Harvard Study on moods and cycles. Arch Gen Psychiatry 2006; 63:385-390.

12.9 Consejo Nacional de Población. La Situac ión Demográfica de México, 2008. Secretaría de

Gobernación.

12.10 Cravioto MC. Controversias sobre terapia hormonal en la menopausia. Gac. Méd. Méx. 2006; 142

(Supl. 2):33-42.

12.11 Cravioto MC, González Macedo J, Martínez Mar tínez L. Menopausia. En: Endocrinología Clínica.

Dorantes Cuéllar A, Martínez Sibaja C, Guzmán Blanno A (Eds.) Editorial El Manual Moderno, 3a. Edición,

México, D.F., México, 2008, pp. 603-612.

12.12 European Medicines Agency Press Office. Press release. European Medicines Agency recommends

withdrawal of medicinal products containing veralipride. 19 July 2007. www.emea.europa.eu/whatsnew.

12.13 FDA Takes Action Against Compounded Menopause Hormone Therapy Drugs. Accessed June 6,

2008.

12.14 Food Processor 8.0. Professional Nutrition An alysis Software and Databases. Copyright © 1987-

2003 ESHA RESEARCH.

12.15 García Vela A, Nava LE, Malacara JM. La edad de la menopausia en la población urbana en la

ciudad de León, Gto. Rev. Invest. Clín. 1987; 39:329-332.

12.16 Garrido Latorre F, Lazcano Ponce EC, López Ca rrillo L, Hernández Avila M. Age of natural

menopause among women in Mexico City. Int J Gynaecol Obstet 1996; 53:159-166.

12.17 Grady D. Management of menopausal symptoms. N Engl J Med 2006; 355:2338-2347.

12.18 Henderson KD, Bernstein L, Henderson B, Kolonel L, Pike MC. Predictors of the timing of natural

menopause in the Multiethnic Cohort Study. Am J Epidemiol 2008; 167:1287-1294.

12.19 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen

plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;

80:605-613.

12.20 Instituto Nacional de las Mujeres, Glosario de Género. México. 2007.

12.21 Kanis JA, Burlet N, Cooper C, Delmas PD, Regi nster JY, Borgstrom F, et al. European guidance for

the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399-428.

12.22 Krebs E, Ensrud K, MacDonald R, Wilt T. Phyt oestrogens for treatment of menopausal symptoms: a

systematic review. Obstet Gynecol 2004; 104:824-836.

12.23 Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone

on climacteric symptoms. BJOG 2002; 109:1109-1114.

12.24 Lindsay R, Gallagher JC, Kleerekoper M, Picka r JH. Effect of lower doses of conjugated equine

estrogens with and without medroxyprogesterone acet ate on bone in early postmenopausal women. JAMA

2002; 287:2668-2676.

12.25 Liu JH. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J

Med 2005; 118 (12 Suppl 2): 88-92.

12.26 Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in

management of hot flashes in survivors of breast ca ncer: a randomized controlled trial. Lancet 2000;

356:2059-2063.

12.27 Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of

fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20:1578-1583.

12.28 MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined

oestrogen/progestogen therapy versus placebo for ho t flushes. The Cochrane Database of Systematic

Reviews 2004, Issue 4. Art. No.:CD002978.pub2.DOI: 10.1002/14651858.CD002978.pub2.

12.29 Malacara JM, Canto de Cetina T, Bassol S, Gonz ález N, Casique L, Vera-Ramírez ML, et al.

Symptoms at pre- and postmenopause in rural and urban women from three states of Mexico. Maturitas 2002;

43:11-19.

12.30 Mosca L, et al. For the Expert Panel/Writing Group. American Heart Association Guidelines.

Evidence-based guidelines for cardiovascular disease pr evention in women. Circula tion 2004; 109:672-693.

www.circulationaha.org

12.31 Muñoz de Chávez M, Ledesma Solano JA, Avila Cu riel A, Calvo C, Castañeda López J, Castro

González I, et al. Los alimentos y sus nutrientes. T ablas de valor nutritivo de alimentos. McGraw-Hill

Interamericana Editores, México, D.F., 2002.

12.32 National Osteoporosis Foundation. Physician's gu ide to prevention and treat ment of osteoporosis.

Washington, D.C. 2003. www.nof.org/phywuide/index.htm.

12.33 National Osteoporosis Foundation. Physician's gu ide to prevention and treat ment of osteoporosis.

Washington, D.C. 2008. www.nof.org/professionals/

12.34 Nelson HD, Humphrey LL, Nygren P, Teutsch SM , Allan JD. Postmenopausal hormone replacement

therapy. Scientific review. JAMA 2002; 288: 872-881.

12.35 Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for

menopausal hot flashes. JAMA 2006; 295:2057-2071.

12.36 Pines A, Sturdee DW, Birkhäuser MH, Schneider HPG, Gambiacciani M, Panay N. On behalf of the

Board of the International Menopause Society. IM S updated recommendations on postmenopausal hormone

therapy. Climacteric 2007; 10:181-194.

12.37 Prior JC. Perimenopause: the complex endocrinol ogy of the menopausal transition. Endocr Rev

1998; 19:397-428.

12.38 Riggs L, Hartmann LC. Selective estrogen-re ceptor modulators-mechanisms of action and

application to clinical practice. N Engl J Med 2003; 348:618-629.

12.39 Rosas Peralta M, Lara Esqueda A, Pastelín Hernánd ez G, Velázquez Monroy O, Martínez Reding J,

Méndez Ortiz A, et al. Re-encuesta nacional de hipert ensión arterial (RENAHTA): Consolidación mexicana de

los factores de riesgo cardiovascular. Cohorte nacional de seguimiento. Arch Cardiol Mex 2005; 75:96-111.

12.40 Schairer C, Lubin J, Troisi R, Sturgeon S, Brin ton L, Hoover R. Menopausal estrogen and estrogen-

progestin replacement therapy and breast cancer risk. JAMA 2000; 283:485-491.

12.41 Schiff I. The effects of progestins on vasomotor flushes. J Reprod Med 1982; 27:498-502.

12.42 Secretaría de Salud. Programa de Acción Específico de Igualdad de Género en Salud 2007-2012.

12.43 Soules MR, Sherman S, Parrott E, Rebar R, Sant oro N, Utian W, et al. Executive summary: Stages

of reproductive aging workshop (STRAW). Park City, Utah, July 2001. Menopause 2001; 8:402-407.

12.44 Stearns V, Beebe KL, Iyengar M, Dube E. Paro xetine controlled release in the treatment of

menopausal hot flashes: a randomized controlled trial. J Am Med Assoc 2003; 289:2827–2834.

12.45 Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalaine n E, Haiva-Mallinen L, et al.

Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month,

placebo-controlled, double-blind study. Menopause 2005; 12:18-26.

12.46 The North American Menopause Society. Tr eatment of menopause-associated vasomotor

symptoms: position statement of the North Americ an Menopause Society. Menopause 2004; 11:11-33.

www.menopause.org.

12.47 The North American Menopause Society. Estrogen and progestogen use in peri-and

postmenopausal women: March 2007 position statem ent of The North American Menopause Society.

Menopause 2007; 14:1-17. www.menopause.org.

12.48 The North American Menopause Society. Estrogen and Progestogen use in peri-and

postmenopausal women: March 2007. Position statem ent of The North Americ an Menopause Society.

Menopause 2007.

12.49 The North American Menopause Society. Estrogen and progestogen use in postmenopausal women:

July 2008 position statement of The North American Menopause Societ y. Menopause 2008; 15:584-603.

www.menopause.org.

12.50 The North American Menopause Society: Re commendations For Estrogens end Progestogens use

in peri-postmenopausal women; October 2004 Position Statement of the North Am erican Menopause Society

2004; 11;589-600.

12.51 The Writing Group for the PEPI trial. Effects of hormone therapy on bone mineral density: results

from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996; 276:1389-1396.

12.52 The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in

postmenopausal women with hysterectomy. The Women's H ealth Initiative randomized controlled trial. JAMA

2004; 291:1701-1712.

12.53 Utian WH. The International Menopause Societ y menopause-related terminology definitions.

Climacteric 1999; 2:284-286.

12.54 Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and

vaginal atrophy with lower doses of conjugated equi ne estrogens and medroxypro gesterone acetate. Fertil

Steril 2001; 75:1065-1079.

12.55 Velasco E, Malacara JM, Cervantes F, de Leó n JD, Dávalos G, Castillo J. Gonadotropins and

prolactin serum levels during the perimenopausal period: Correlation with diverse factor. Fertil Steril 1990;

53:56-60.

12.56 WHO Technical Report Series No 863. Geneva, World Health Organization, 19996.

12.57 World Health Organization, Department of Reprodu ctive Health and Research. Medical eligibility

criteria for contraceptive use. 3rd. edition. World Health Organi zation, Geneva, Switzerland, 2004.

www.who.int/reproductive-health/publications.

12.58 World Health Organization, Information Exchan ge System. Alert No. 116. More risks than benefits

with veralipride; marketing authorization withdrawn for all medicinal products containing veralipride. July 2007.

12.59 World Health Organization: Research on the men opause in the 1990¨s Report of WHO Scientific

Group.

12.60 World Health Organization Scientific Group. Research on the menopause in the 1990s. WHO

Tecnichal Report Series No 866. World Health Organization, Geneva, Switzerland, 1996.

12.61 Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus

progestin in healthy postmenopausal women: principal re sults from the Women's Health Initiative randomized

controlled trial. JAMA 2002; 288:321-333.

12.62 Writing Group for the PEPI Trial. Effect of estrogen or estrogen/ progestin regimen on heart disease

risk factor in postmenopausal women: The Postmeno pausal Estrogen/Progestin Intervention (PEPI) Trial.

JAMA 1995; 273:199-208.